# Direct vasodilators (hydralazine, minoxidil)

Drug · id `cardio:direct-vasodilators-hydralazine-minoxidil` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Direct vasodilators; Arteriolar vasodilator

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

Medicines that lower blood pressure by relaxing the muscle in blood vessel walls. The US label read for hydralazine lists essential hypertension. The label read for minoxidil limits its use to high blood pressure that is symptomatic or damaging organs and that is not manageable with maximum doses of a diuretic plus two other blood pressure medicines, and it carries a boxed warning about serious adverse effects.

## Technical summary

Class page. MeSH descriptor D014665 (Vasodilator Agents, last updated 2020-05-27) is a broad match, because it covers every medicine used to dilate blood vessels and not only these two. Two US labels were read: hydralazine hydrochloride tablets (application ANDA086242, effective 2025-12-10 in openFDA) and minoxidil tablets (application ANDA072708, effective 2026-01-21 in openFDA; established pharmacologic class Arteriolar Vasodilator). Both are generic labels, not the original brand. The hydralazine label says its mechanism is not fully understood. A separate claim records the minoxidil boxed warning. The label texts read state no age range for their uses. This page gives no dose, no trial result and no guideline statement. Medicines of the group that have their own pages are filed under it.

## Claims, with the population each applies to

## Context: People treated with minoxidil tablets for hypertension, as described in the boxed warning of a US label

Recipient: Recipient not specified; Population: Patients treated with minoxidil tablets, as the boxed warning of the label describes the risk.; Care setting: Prescription medicine, as described in the US label; Geography: United States (US drug label); Life stage: Not stated in the passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The label of minoxidil tablets (AvKARE, application ANDA072708; the version dated 2026-01-21 in openFDA) carries a boxed warning. It says the tablets contain a powerful antihypertensive agent that may produce serious adverse effects, and that minoxidil can cause pericardial effusion, occasionally progressing to tamponade, and angina pectoris may be exacerbated.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients treated with minoxidil tablets, as the boxed warning of the label describes the risk.; Care setting: Prescription medicine, as described in the US label; Geography: United States (US drug label); Life stage: Not stated in the passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records two statements of the label's boxed warning only. The boxed warning also lists other effects and steps for managing treatment; they are not repeated here. The label read is a generic label, not the original brand, and states no age range. Other warnings, contraindications, interactions and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for minoxidil tablets, AvKARE label: indications and class description (Regulator, edition The openFDA drug label record for set id 02d7399f-94cc-f718-f214-587301edd138 (manufacturer AvKARE, application ANDA072708), returned on 2026-11-09. The label text is dated 2026-01-21 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2202d7399f-94cc-f718-f214-587301edd138%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\]. Retrieved 2026-11-09T13:17:47Z. Source state: Current. Version fingerprint: 02054d47d2e219137166fc69012547112cfc3ee1d6b50c0298a6163ea9658e9e.
     How it applies: Serious adverse effects, pericardial effusion and angina.
  2. Background: openFDA drug label record for minoxidil tablets, AvKARE label: indications and class description (Regulator, edition The openFDA drug label record for set id 02d7399f-94cc-f718-f214-587301edd138 (manufacturer AvKARE, application ANDA072708), returned on 2026-11-09. The label text is dated 2026-01-21 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2202d7399f-94cc-f718-f214-587301edd138%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:47Z. Source state: Current. Version fingerprint: 02054d47d2e219137166fc69012547112cfc3ee1d6b50c0298a6163ea9658e9e.
     How it applies: Effective date of the label text read, 20260121.

## Context: People with hypertension, for minoxidil only hypertension that is symptomatic or damaging organs and not manageable with maximum doses of a diuretic plus two other drugs, as described in two US labels

Recipient: Recipient not specified; Population: Patients described in the indications sections of the two labels: patients with essential hypertension (hydralazine), and patients with hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs (minoxidil).; Care setting: Prescription medicine, as described in the US labels; Geography: United States (US drug labels); Life stage: Not stated in the passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### Two US generic labels were read. The label of hydralazine hydrochloride tablets (Chartwell RX, LLC, application ANDA086242; the version dated 2025-12-10 in openFDA) lists essential hypertension, alone or as an adjunct, and says the medicine apparently lowers blood pressure through a peripheral vasodilating effect, a direct relaxation of vascular smooth muscle. The label of minoxidil tablets (AvKARE, application ANDA072708; the version dated 2026-01-21 in openFDA) calls the medicine an antihypertensive peripheral vasodilator, and says that because of the potential for serious adverse effects it is indicated only for hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. MeSH describes vasodilator agents as drugs used to cause dilation of the blood vessels.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications sections of the two labels: patients with essential hypertension (hydralazine), and patients with hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs (minoxidil).; Care setting: Prescription medicine, as described in the US labels; Geography: United States (US drug labels); Life stage: Not stated in the passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what two US generic labels say. It is not a finding about how well either medicine works, and no trial result is recorded for it in this atlas. Neither label is the original brand. The labels read state no age range. The minoxidil boxed warning is recorded in a separate claim. Other warnings, contraindications, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220c7f9bd0-6c0a-4521-b77a-3582faa96874%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], INDICATIONS AND USAGE. Retrieved 2026-11-09T13:17:45Z. Source state: Current. Version fingerprint: 4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0.
     How it applies: Hydralazine: essential hypertension.
  2. Supports: openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220c7f9bd0-6c0a-4521-b77a-3582faa96874%22&limit=1>
     Locator: results\[0\].clinical\_pharmacology\[0\], CLINICAL PHARMACOLOGY. Retrieved 2026-11-09T13:17:45Z. Source state: Current. Version fingerprint: 4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0.
     How it applies: Hydralazine: peripheral vasodilating effect.
  3. Background: openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220c7f9bd0-6c0a-4521-b77a-3582faa96874%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:45Z. Source state: Current. Version fingerprint: 4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0.
     How it applies: Effective date of the label text read, 20251210.
  4. Supports: openFDA drug label record for minoxidil tablets, AvKARE label: indications and class description (Regulator, edition The openFDA drug label record for set id 02d7399f-94cc-f718-f214-587301edd138 (manufacturer AvKARE, application ANDA072708), returned on 2026-11-09. The label text is dated 2026-01-21 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2202d7399f-94cc-f718-f214-587301edd138%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], INDICATIONS AND USAGE. Retrieved 2026-11-09T13:17:47Z. Source state: Current. Version fingerprint: 02054d47d2e219137166fc69012547112cfc3ee1d6b50c0298a6163ea9658e9e.
     How it applies: Minoxidil: limited use in hypertension.
  5. Supports: openFDA drug label record for minoxidil tablets, AvKARE label: indications and class description (Regulator, edition The openFDA drug label record for set id 02d7399f-94cc-f718-f214-587301edd138 (manufacturer AvKARE, application ANDA072708), returned on 2026-11-09. The label text is dated 2026-01-21 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2202d7399f-94cc-f718-f214-587301edd138%22&limit=1>
     Locator: results\[0\].description\[0\], DESCRIPTION. Retrieved 2026-11-09T13:17:47Z. Source state: Current. Version fingerprint: 02054d47d2e219137166fc69012547112cfc3ee1d6b50c0298a6163ea9658e9e.
     How it applies: Minoxidil: antihypertensive peripheral vasodilator.
  6. Background: openFDA drug label record for minoxidil tablets, AvKARE label: indications and class description (Regulator, edition The openFDA drug label record for set id 02d7399f-94cc-f718-f214-587301edd138 (manufacturer AvKARE, application ANDA072708), returned on 2026-11-09. The label text is dated 2026-01-21 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2202d7399f-94cc-f718-f214-587301edd138%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:47Z. Source state: Current. Version fingerprint: 02054d47d2e219137166fc69012547112cfc3ee1d6b50c0298a6163ea9658e9e.
     How it applies: Effective date of the label text read, 20260121.
  7. Supports: MeSH scope note for descriptor D014665 (Vasodilator Agents) (Dataset, edition MeSH linked-data record of the preferred concept M0022559 of descriptor D014665, fetched 2026-11-09. The scope note is on this concept record, not on the descriptor record.) <https://id.nlm.nih.gov/mesh/M0022559>
     Locator: scopeNote.@value. Retrieved 2026-11-09T13:15:50Z. Source state: Current. Version fingerprint: c3651b01270284b23f245ca88fd1185739a299f3cecd5a0f220667884e135043.
     How it applies: MeSH scope note: what vasodilator agents are.

## Connected pages

- Two US labels list treating high blood pressure as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-vasodilator-labels-indications` and its context]
- Blood pressure lowering medicine, the care strategy: Blood pressure lowering medicine (`cardio:bp-lowering-medicine`)
- Files under this front: Medicines (`cardio:front-medicines`)
- Has subtype: Hydralazine (`cardio:hydralazine`)

## Provenance

Content hash: e7eebdace104acaa41f548a3d6498183e959a17d1c76174d3fa7dca63899f0aa
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-09
